{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:27:57Z","timestamp":1781008077676,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,23]]},"DOI":"10.7759\/cureus.14654","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T04:35:38Z","timestamp":1619238938000},"source":"Crossref","is-referenced-by-count":3,"title":["Extra-Nodal, Nasal, Natural Killer T-Cell Lymphoma Treated With a Checkpoint Inhibitor: A Case Report of a Sustained Complete Response"],"prefix":"10.7759","author":[{"given":"Radwan","family":"Diab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Adcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalil","family":"Choucair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc V","family":"Truong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190903186502","article-title":"Extranodal natural killer\/T-cell lymphoma: current concepts in biology and treatment","volume":"50","author":"Kohrt H","year":"2009","unstructured":"Kohrt H, Advani R. Extranodal natural killer\/T-cell lymphoma: current concepts in biology and treatment. Leuk Lymphoma. 2009, 50:1773-84. 10.3109\/10428190903186502","journal-title":"Leuk Lymphoma"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-016-0355-9","article-title":"Extranodal NK\/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases","volume":"11","author":"Haverkos BM","year":"2016","unstructured":"Haverkos BM, Pan Z, Gru AA, et al.. Extranodal NK\/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases. Curr Hematol Malig Rep. 2016, 11:514-27. 10.1007\/s11899-016-0355-9","journal-title":"Curr Hematol Malig Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams SV","year":"2016","unstructured":"Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016, 34:963-71. 10.1200\/JCO.2015.63.5540","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2019.00141","article-title":"Extranodal natural killer\/T-cell lymphoma, nasal type: basic science and clinical progress","volume":"7","author":"Harabuchi Y","year":"2019","unstructured":"Harabuchi Y, Takahara M, Kishibe K, Nagato T, Kumai T. Extranodal natural killer\/T-cell lymphoma, nasal type: basic science and clinical progress. Front Pediatr. 2019, 7:141. 10.3389\/fped.2019.00141","journal-title":"Front Pediatr"},{"key":"ref5","unstructured":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) - Lymphoma Classification in the Third Millennium. (2017). Accessed. March 2, 2021: http:\/\/www.qml.com.au\/Portals\/0\/PDF\/Newsletters\/QML_NL_4_2012.pdf."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0717-6","article-title":"Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL)","volume":"12","author":"Somasundaram N","year":"2019","unstructured":"Somasundaram N, Lim JQ, Ong CK, Lim ST. Pathogenesis and biomarkers of natural killer T cell lymphoma (NKTL). J Hematol Oncol. 2019, 12:28. 10.1186\/s13045-019-0717-6","journal-title":"J Hematol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0452-9","article-title":"The diagnosis and management of NK\/T-cell lymphomas","volume":"10","author":"Tse E","year":"2017","unstructured":"Tse E, Kwong YL. The diagnosis and management of NK\/T-cell lymphomas. J Hematol Oncol. 2017, 10:85. 10.1186\/s13045-017-0452-9","journal-title":"J Hematol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639336","article-title":"Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study","volume":"126","author":"Yang Y","year":"2015","unstructured":"Yang Y, Zhu Y, Cao JZ, et al.. Risk-adapted therapy for early-stage extranodal nasal-type NK\/T-cell lymphoma: analysis from a multicenter study. Blood. 2015, 126:1424-32. 10.1182\/blood-2015-04-639336","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1108415","article-title":"Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK\/T-cell lymphoma","volume":"57","author":"Dong LH","year":"2016","unstructured":"Dong LH, Zhang LJ, Wang WJ, et al.. Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK\/T-cell lymphoma. Leuk Lymphoma. 2016, 57:1600-6. 10.3109\/10428194.2015.1108415","journal-title":"Leuk Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong YL","year":"2012","unstructured":"Kwong YL, Kim WS, Lim ST, et al.. SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012, 120:2973-80. 10.1182\/blood-2012-05-431460","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11135","article-title":"The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)\/T-cell lymphoma, nasal type","volume":"7","author":"Zhang L","year":"2016","unstructured":"Zhang L, Li S, Jia S, et al.. The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)\/T-cell lymphoma, nasal type. Oncotarget. 2016, 7:58396-404. 10.18632\/oncotarget.11135","journal-title":"Oncotarget"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose J","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008, 26:4124-30. 10.1200\/JCO.2008.16.4558","journal-title":"J Clin Oncol"},{"key":"ref13","article-title":"Selection of new immunotherapy targets for NK\/T cell lymphoma","volume":"12","author":"Lv K","year":"2020","unstructured":"Lv K, Li X, Yu H, Chen X, Zhang M, Wu X. Selection of new immunotherapy targets for NK\/T cell lymphoma. Am J Transl Res. 2020, 12:7034-47.","journal-title":"Am J Transl Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00139","article-title":"Novel Immunotherapy options for extranodal NK\/T-cell lymphoma","volume":"8","author":"Hu B","year":"2018","unstructured":"Hu B, Oki Y. Novel Immunotherapy options for extranodal NK\/T-cell lymphoma. Front Oncol. 2018, 8:139. 10.3389\/fonc.2018.00139","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2627-9","article-title":"Complete remission of refractory disseminated NK\/T cell lymphoma with brentuximab vedotin and bendamustine","volume":"95","author":"Poon LM","year":"2016","unstructured":"Poon LM, Kwong YL. Complete remission of refractory disseminated NK\/T cell lymphoma with brentuximab vedotin and bendamustine. Ann Hematol. 2016, 95:847-9. 10.1007\/s00277-016-2627-9","journal-title":"Ann Hematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1605684","article-title":"Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma","volume":"375","author":"Hari P","year":"2016","unstructured":"Hari P, Raj RV, Olteanu H. Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma. N Engl J Med. 2016, 375:1501-2. 10.1056\/NEJMc1605684","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1364","article-title":"Treatment of relapsed extranodal natural killer\/T-cell lymphoma with bortezomib plus fludarabine","volume":"7","author":"Chen C","year":"2017","unstructured":"Chen C, He H. Treatment of relapsed extranodal natural killer\/T-cell lymphoma with bortezomib plus fludarabine. Mol Clin Oncol. 2017, 7:525-8. 10.3892\/mco.2017.1364","journal-title":"Mol Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong YL","year":"2017","unstructured":"Kwong YL, Chan TSY, Tan D, et al.. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase. Blood. 2017, 129:2437-42. 10.1182\/blood-2016-12-756841","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2015.09.002","article-title":"Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies","volume":"1865","author":"Xia Y","year":"2016","unstructured":"Xia Y, Medeiros LJ, Young KH. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta. 2016, 1865:58-71. 10.1016\/j.bbcan.2015.09.002","journal-title":"Biochim Biophys Acta"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders K","year":"2015","unstructured":"Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015, 41:503-10. 10.1016\/j.ctrv.2015.03.011","journal-title":"Cancer Treat Rev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/54719-extra-nodal-nasal-natural-killer-t-cell-lymphoma-treated-with-a-checkpoint-inhibitor-a-case-report-of-a-sustained-complete-response","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:02Z","timestamp":1707506882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/54719-extra-nodal-nasal-natural-killer-t-cell-lymphoma-treated-with-a-checkpoint-inhibitor-a-case-report-of-a-sustained-complete-response"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.14654","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,23]]}}}